MedTrace Logo

Dopaminergic Receptors in Sydenham's Chorea

NCT04084977 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2019-09-10

No results posted yet for this study

Summary

Sydenham's chorea (SC) is a post-streptococcal, neuropsychiatric disorder associated with anti-neuronal antibodies. The investigators demonstrated elevated anti-D1-receptor (D1R) and anti-D2-receptor (D2R) antibodies titers compared to controls using ELISA. Similarly, the investigators found antibodies to surface D2R in neuropsychiatric, autoimmune disorders, including SC using cell-based assays. The investigators hypothesize that these autoantibodies cause neuropsychiatric symptoms by inducing intracellular signaling changes resulting in altered dopaminergic neurotransmission. To check this, the investigators will test whether sera from patients with SC alter dopaminergic signaling pathways. The investigators will examine sera from 30 SC patients with active symptoms and 30 age-matched healthy controls. Patients with SC will be assessed for severity of neuropsychiatric symptoms using UFMG Sydenham's Chorea Rating Scale. Controls with evidence of streptococcal infections or autoimmune disorders will be excluded. Sera will be examined for anti-D1R and anti-D2R antibodies. Signaling studies will assess sera impact on 1) calcium/calmodulin-dependent protein kinase II activity in human neuronal cells. 2) dopamine D1/D2 receptors signaling using cAMP assays in transfected cell lines. The investigators will examine the correlation between modified signaling and clinical symptoms.

Conditions

  • Sydenham Chorea
  • Strep Throat

Interventions

DIAGNOSTIC_TEST

Antibody detection

detecting anti bodies against D1, D2 receptor, tubolin Lysoganglioside

Sponsors & Collaborators

  • University of Oklahoma

    collaborator OTHER

  • Shaare Zedek Medical Center

    lead OTHER

Eligibility

Min Age
2 Years
Max Age
40 Years
Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-01
Primary Completion
2019-12-30
Completion
2021-12-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04084977 on ClinicalTrials.gov